Select Bibliography

Filter by any of these (after searching):

Blood Adv

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 17 items

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Advani, Anjali S. , Larsen, Eric , Laumann, Kristina ... - - Blood Adv - 2021

Manuscript - Secondary - Primary - Leukemia - CALGB-10403 , COG-AALL0232

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018

Manuscript - Primary - Primary - Leukemia - CALGB-10404

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Fobare, Sydney , Kohlschmidt, Jessica , Ozer, Hatice Gulcin ... - - Blood Adv - 2022

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.

Larkin, Karilyn , Nicolet, Deedra , Kelly, Benjamin J ... - - Blood Adv - 2022

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Marcucci, Guido , Geyer, Susan , Laumann, Kristina , Zhao, Weiqiang ... - - Blood Adv - 2020

Manuscript - Primary - Primary - Leukemia - CALGB-10801 , CALGB-20202

Enrollment Disparities and Outcomes of Hispanic AYA ALL Patients Treated on a U.S Intergroup Trial: A Comparison of the CALGB 10403 Cohort with U.S. Population Data (Alliance)

Muffly, Lori , Yin, Jun , Jacobson, Sawyer , Wall, Anna ... - - Blood Adv - 2022

Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10403

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Papaioannou, Dimitrios , Volinia, Stefano , Nicolet, Deedra ... - - Blood Adv - 2020

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - C8721 , C8821 , C9022 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-9022 , CALGB-9120 , CALGB-9222

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.

Ritchie, Ellen K , Klepin, Heidi D , Storrick, Elizabeth ... - - Blood Adv - 2022

Manuscript - Primary - Primary - Older Adult - CALGB-361101 , CALGB-11002

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Roboz, Gail J. , Mandrekar, Sumithra J. , Desai, Pinkal ... - - Blood Adv - 2018

Manuscript - Primary - Primary - Leukemia - CALGB-11002

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina ... - - Blood Adv - 2017

Manuscript - Primary - Primary - Leukemia - CALGB-11001

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

Vasu, Sumithira , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - - Blood Adv - 2018

Manuscript - Secondary-not-in-original - Meta-Analysis - Leukemia - C8221 , C8461 , C8525 , C8721 , C8821 , C9022 , C9720 , CALGB-19808 , CALGB-8923 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - - Blood Adv - 2021

Manuscript - Secondary - Long-Term-Followup - Myeloma - AFT-29

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Voso, Maria Teresa , Larson, Richard A. , Jones, Dan ... - - Blood Adv - 2020

Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William ... - - Blood Adv - 2021

Manuscript - Primary - Primary - Leukemia - CALGB-10201

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Walker, Christopher J. , Mrózek, Krzysztof , Ozer, Hatice Gulcin ... - - Blood Adv - 2021

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - C8525 , C8721 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-9222 , CALGB-9621

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL

Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoffrey L. ... - - Blood Adv - 2021

Manuscript - Primary - Primary - Leukemia - CALGB-10701

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Yin, Jun , LaPlant, Betsy , Uy, Geoffrey L. , Marcucci, Guido ... - - Blood Adv - 2019

Manuscript - Primary - Primary - Leukemia - A151614 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-10801 , CALGB-11001